Experimental Ebola vaccine regimen induced durable immune response, study finds

(NIH/National Institute of Allergy and Infectious Diseases) A two-vaccine regimen to protect against Ebola virus disease induced an immune response that persisted for approximately one year in healthy adult volunteers, according to results from a Phase 1 clinical trial published March 14 in JAMA. The investigational vaccines included Ad26.ZEBOV, developed by Janssen Vaccines & Prevention B.V., of the Janssen Pharmaceutical Companies of Johnson & Johnson, and MVA-BN-Filo, developed by Bavarian No...